This webpage was developed to provide drug risk information which has come under review by the PMDA/MHLW. Information provided here is as follows:
Posted Date | Nonproprietary Name | Risk Information Ongoing Evaluation | Related Information | Investigation Results |
---|---|---|---|---|
January 20, 2023 | Tazobactam/piperacillin hydrate | Haemophagocytic lymphohistiocytosis (haemophagocytic syndrome) | - | - |
Liraglutide (genetical recombination) Exenatide Lixisenatide Dulaglutide (genetical recombination) Semaglutide (genetical recombination) Insulin degludec (genetical recombination)/liraglutide (genetical recombination) Insulin glargine (genetical recombination)/lixisenatide Tirzepatide |
Cholecystitis, cholangitis, cholestatic jaundice | - | - | |
December 26, 2013 | Recombinant absorbed bivalent human papillomavirus-like particle vaccine Recombinant adsorbed quadrivalent human papillomavirus virus-like particle vaccine |
Symptoms related to pain | - | Summary of the Report on the Surveillance Results of HPV Vaccines |
Posted Date | Nonproprietary Name | Risk Information Ongoing Evaluation | Related Information | Investigation Results |
---|---|---|---|---|
November 30, 2011 | Bevacizumab (genetical recombination) | Japan's view on Avastin (bevacizumab) for breast cancer indication | Press Announcement from the FDA Review report of AVASTIN 100mg/4mL Intravenous Infusion and AVASTIN 400mg/16mL Intravenous Infusion on July 14, 2011 (Japanese text only) |
- |